Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI claims largely lack support from the FDA label. A minority of claims are supported or partially supported by the label sections; the majority are not supported.
Category Scores
Accurate Statements
Mirtazapine’s sedating effect mainly comes from blocking histamine H1 receptors.
12.2
At higher doses, mirtazapine also has stronger effects on other receptors (e.g., serotonergic 5-HT2/5-HT3, α2-adrenergic).
12.1,12.2
These can counteract the sedating influence to some degree, or simply add new side‑effect profiles (e.g., increased appetite, weight gain) that mask the sedation.
5.7
Concomitant medications: Other sedatives (like benzodiazepines or antihistamines) or stimulants can alter how you feel at each dose.
7
Time to peak: Mirtazapine reaches peak plasma levels roughly 2–4 hours after ingestion.
12.3
Unsupported Statements
Once those receptors are largely blocked, you reach a ceiling of sedation.
No label statement describes a saturation ceiling for sedation tied to H1 receptor occupancy.
Adding more drug (e.g., going from 7.5 mg to 15 mg) won’t make you noticeably sleepier because the H1 sites are already saturated.
No label support for a dose- or H1-saturation ceiling effect on sedation.
Metabolism: People metabolize drugs at different rates.
Label does not explicitly present a standalone statement framing metabolic variability in this general form within the cited sections.
If your body clears the drug quickly, a higher dose may not stay long enough in the system to produce extra sedation.
No explicit label statement linking clearance rate to reduced sedation at higher doses.
Tolerance: If you’ve been on mirtazapine for a while, your brain may have developed a tolerance to the sedative effect.
Label does not explicitly describe tolerance to sedation.
The 15 mg dose might be just enough to trigger other side-effects that make you feel less sleepy, even if the drug is still in your system.
No specific label claim about higher-dose side-effects offsetting sedation in this context.
A 15 mg dose may simply maintain a steadier level of the drug, leading to a more constant but less burst-like sedative effect compared to the 7.5 mg dose, which can produce a sharper, more noticeable dip.
No label statement describing dose-dependent temporal sedative profiles in this manner.
Expectation: If you’re expecting a higher dose to make you sleepier, you might actually feel more awake because you’re hyper-aware of the side-effects (e.g., increased appetite) that can counterbalance sedation.
No label guidance on nocebo/expectation effects affecting sedation.
Placebo vs. nocebo: A higher dose can sometimes feel more potent but also more busy on your nervous system, which can feel less sleepy.
No label basis for placebo/nocebo interpretations of dose-related sleepiness.
Bottom line: While the sedative effect of mirtazapine does increase with dose up to a point, it plateaus once histamine H1 receptors are saturated.
No explicit label statement about a saturation plateau for sedation at certain H1 occupancy.
After that, adding more drug mainly increases other side-effects and may even dampen the subjective feeling of sleepiness.
No label statement confirming this exact progression.
Individual metabolism, tolerance, and interactions with other meds can further explain why you felt more sedated at 7.5 mg than at 15 mg.
Label discusses variability and interactions generally; no direct claim about this specific comparison.
Contradictions
Important Omissions
Approved indication (major depressive disorder) and full dosing/administration guidance are not addressed.
Importance:
Moderate
No Boxed Warnings or detailed safety warnings are cited in relation to the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on label alignment; no new safety signals beyond those described in label sections were inferred.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Majority of claims are not supported by the label; only a few are supported or partially supported.
Suggested Improvement
Limit claims to those explicitly supported by label sections (e.g., H1 antagonism in 12.2, receptor activity in 12.1/12.2, pharmacokinetics 12.3, weight/appetite data in 5.7, drug interactions in 7). Avoid speculative dose-specific sleepiness or nocebo/placebo interpretations; reference exact label sections.